If you’d talked to Joe Heyman around the 2000s, you might have taken him as a telemedicine naysayer. Back then, the Massachusetts OB-GYN was highly skeptical of the rash of new services sprouting up to remotely connect patients and physicians. He was wary, he told STAT, of patients “calling a total stranger and asking for clinical care,” and worried about building trust when a new doctor picked up the phone every time. He never once conducted a visit via video by the time he retired from seeing patients in 2014.
He only wishes he’d had the chance.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
